Home » Authors » Rachelle H.B. Fishman

Articles by Rachelle H.B. Fishman

Israeli Biotech Continues Growth With Private, Government Support

May 7, 2003

By Rachelle H.B. Fishman

Ester Neuroscience Gets Good Results In Early Antisense Trial

April 9, 2003

By Rachelle H.B. Fishman

Chiasma Gets First Biotech Investment From InnoMed

April 9, 2003

By Rachelle H.B. Fishman

Bioline Therapeutics Formed By Israeli Groups With $11M Funding

April 9, 2003

By Rachelle H.B. Fishman

Gamida-Cell, Teva Enter Deal To Develop Stem Cell Product

March 26, 2003

By Rachelle H.B. Fishman

MediWound's Burn Agent Gains Orphan Status, Starts Phase IIb

March 5, 2003

By Rachelle H.B. Fishman

Ester Neuroscience Successfully Delivers Antisense Drug Orally

Jan. 8, 2003

By Rachelle H.B. Fishman

Founders Staying In Israel As Keryx Moves Operations To U.S.

Jan. 1, 2003

By Rachelle H.B. Fishman

Japanese, Israeli Firms Unite On Tyrosine Kinase Blockers

Dec. 11, 2002

By Rachelle H.B. Fishman

Competitors Managing Israel's First Private Biotech Incubators

Dec. 4, 2002

By Rachelle H.B. Fishman

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 9, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 9, 2026.
ADCs’ breakout 2025 and their still-unfinished potential
BioWorld Science
Over the course of the year, and continuing into the latest scientific meetings, an extraordinary breadth of new antibody-drug conjugate (ADC) designs was...
Development and characterization of anti-CD19 in vivo CAR T therapy
BioWorld Science
Shenzhen Grit Biotechnology Co. Ltd. and Shanghai Vitalgen Biopharma Co. Ltd. recently presented their work to develop and evaluate a novel anti-CD19 in vivo CAR...
Preclinical results of anti-ADAMTS13 antibody in acquired von Willebrand syndrome
BioWorld Science
The acquired von Willebrand syndrome (AVWS) is a rare bleeding disorder with laboratory findings similar to those of inherited von Willebrand disease. Researchers...